They further suggest that targeting extracellular IGFBP-5 in diseases such as SSc or IPF where IGFBP-5 levels are elevated may be a more appropriate strategy for ameliorating fibrosis. This evidence concerns the gene IGFBP5 and systemic sclerosis.